BioSpace News Archive

Collaboration includes joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity Catalent to hire 300 additional personnel to meet operational readiness and 24x7 manufacturing schedules

EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, will present data on its lead therapeutic program for patients with the most severe form of mucopolysaccharidosis type I (MPS I), known as Hurler syndrome, at the 23rd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on Tuesday, May 12, 2020

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, announced the appointment of Satnam Alag, PhD, as Senior Vice President of Software Engineering.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2020 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2020. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2020 financial results and to provide a corporate update. The conference call may be accessed by dialing (844) 534-7313 for d

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development company, is pleased to announce that Dr. Mark Williams, Chief Science Officer of Algernon, will be making a presentation entitled “The Science of Ifenprodil” on a special BioPub webcast today April 29th, 2020 hosted by Dr. KSS, MD, PhD at Noon EDT. The Company invites intereste

Partnership with global telemedicine leader MediOrbis creates a social distancing compliant, complete care Dario solution

Gilead Sciences. Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational antiviral remdesivir for the treatment of COVID-19. We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing. Remdesivir is not yet licensed or approved anywhere globa

Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of cancer and other life-threatening diseases, today announced that Chimerix, Inc., to whom it licensed worldwide rights for the development and commercialization of its lead product, CX-01 (now known as DS

An oral dietary supplement designed to help skin fight photoaging from the inside out.

CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Single and Double-Digit Royalties, From the Sales of Arimoclomol